目前临床有许多有效的治疗青光眼的药物，但是由于传统给药系统的限制，导致了较低的生物利用度、较差的患者依从性以及一些毒副作用。药物缓释系统通过局部滴眼、眼内或结膜下注射、手术植入等手段可实现在病灶局部缓慢释药。聚乳酸-乙醇酸、脂质体、壳聚糖等具有生物降解性，生物相容性的缓释材料逐渐成为研究的热点，有可能成为治疗青光眼药物不可取代的载体。

There are much effective medicine currently available for treating glaucoma. However, their clinical efficacy is limited by traditional delivery systems, resulting in poor bioavailability, poor patient adherence, and increased side effects. By topical eye drops, intraocular injection or subconjunctival injection, and surgical implants, drug delivery systems can realize the purpose of sustained-release in target tissue. Poly(DL-lactide-co-glycolide), liposome, chitosan and other sustained-release materials with biodegradation and biocompatibility are becoming research focus gradually. Drug delivery systems have the possibility to become irreplaceable carriers for glaucoma therapy medicine.

中国重庆市科技攻关计划资助项目（No.CSTC-2010AC5029）；军队“十二五”面上资助项目（No.CWSLLJ137）